Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses

Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 218; no. 12
Main Authors Shinnakasu, Ryo, Sakakibara, Shuhei, Yamamoto, Hiromi, Wang, Po-hung, Moriyama, Saya, Sax, Nicolas, Ono, Chikako, Yamanaka, Atsushi, Adachi, Yu, Onodera, Taishi, Sato, Takashi, Shinkai, Masaharu, Suzuki, Ryosuke, Matsuura, Yoshiharu, Hashii, Noritaka, Takahashi, Yoshimasa, Inoue, Takeshi, Yamashita, Kazuo, Kurosaki, Tomohiro
Format Journal Article
LanguageEnglish
Published United States Rockefeller University Press 06.12.2021
Subjects
Amino Acid Motifs
Animals
Antibodies, Viral - immunology
Broadly Neutralizing Antibodies - immunology
COVID-19 - genetics
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Female
Humans
Infectious Disease and Host Defense
Male
Mice
Mice, Inbred BALB C
Polysaccharides - genetics
Polysaccharides - immunology
Protein Domains
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Severe acute respiratory syndrome-related coronavirus - genetics
Severe acute respiratory syndrome-related coronavirus - immunology
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Online AccessGet full text

Cover

Abstract Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD–specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.
AbstractList Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD-specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.
Shinnakasu et al. show that the glycan engineering immunogens of SARS-CoV-2 spike receptor-binding domain (RBD) elicited higher proportions of the core-RBD-specific germinal center (GC) B cells and antibodies, thereby manifesting significant neutralizing activity not only for SARS-CoV-2 but also for more broad SARS-related viruses. Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD–specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.
Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD-specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD-specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.
Author Inoue, Takeshi
Shinkai, Masaharu
Onodera, Taishi
Yamamoto, Hiromi
Wang, Po-hung
Adachi, Yu
Sax, Nicolas
Shinnakasu, Ryo
Yamanaka, Atsushi
Hashii, Noritaka
Ono, Chikako
Moriyama, Saya
Takahashi, Yoshimasa
Yamashita, Kazuo
Suzuki, Ryosuke
Sato, Takashi
Matsuura, Yoshiharu
Sakakibara, Shuhei
Kurosaki, Tomohiro
AuthorAffiliation 12 Laboratory for Lymphocyte Differentiation, Research Center for Allergy and Immunology, RIKEN, Yokohama, Japan
2 Laboratory of Immune Regulation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
10 Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
5 Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
6 Laboratory of Virus Control, Center for Infectious Diseases Education and Research, Osaka University, Osaka, Japan
13 Center for Infectious Diseases Education and Research, Osaka University, Osaka, Japan
4 KOTAI Biotechnologies, Inc., Osaka, Japan
7 Mahidol-Osaka Center for Infectious Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
3 Reseach Center for Drug and Vaccine Development, National Institute of Infection Diseases, Tokyo, Japan
8 Mahidol-Osaka Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
9 Tok
AuthorAffiliation_xml – name: 11 Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kawasaki, Japan
– name: 6 Laboratory of Virus Control, Center for Infectious Diseases Education and Research, Osaka University, Osaka, Japan
– name: 9 Tokyo Shinagawa Hospital, Tokyo, Japan
– name: 10 Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
– name: 2 Laboratory of Immune Regulation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
– name: 8 Mahidol-Osaka Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
– name: 3 Reseach Center for Drug and Vaccine Development, National Institute of Infection Diseases, Tokyo, Japan
– name: 12 Laboratory for Lymphocyte Differentiation, Research Center for Allergy and Immunology, RIKEN, Yokohama, Japan
– name: 7 Mahidol-Osaka Center for Infectious Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
– name: 5 Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
– name: 1 Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
– name: 13 Center for Infectious Diseases Education and Research, Osaka University, Osaka, Japan
– name: 4 KOTAI Biotechnologies, Inc., Osaka, Japan
Author_xml – sequence: 1
  givenname: Ryo
  orcidid: 0000-0002-5369-3424
  surname: Shinnakasu
  fullname: Shinnakasu, Ryo
– sequence: 2
  givenname: Shuhei
  orcidid: 0000-0003-3157-5870
  surname: Sakakibara
  fullname: Sakakibara, Shuhei
– sequence: 3
  givenname: Hiromi
  orcidid: 0000-0002-3495-9936
  surname: Yamamoto
  fullname: Yamamoto, Hiromi
– sequence: 4
  givenname: Po-hung
  orcidid: 0000-0001-6770-1918
  surname: Wang
  fullname: Wang, Po-hung
– sequence: 5
  givenname: Saya
  orcidid: 0000-0003-2057-9198
  surname: Moriyama
  fullname: Moriyama, Saya
– sequence: 6
  givenname: Nicolas
  orcidid: 0000-0003-3241-4737
  surname: Sax
  fullname: Sax, Nicolas
– sequence: 7
  givenname: Chikako
  orcidid: 0000-0002-3965-6715
  surname: Ono
  fullname: Ono, Chikako
– sequence: 8
  givenname: Atsushi
  orcidid: 0000-0002-2757-2792
  surname: Yamanaka
  fullname: Yamanaka, Atsushi
– sequence: 9
  givenname: Yu
  orcidid: 0000-0002-8573-987X
  surname: Adachi
  fullname: Adachi, Yu
– sequence: 10
  givenname: Taishi
  orcidid: 0000-0002-7079-3339
  surname: Onodera
  fullname: Onodera, Taishi
– sequence: 11
  givenname: Takashi
  orcidid: 0000-0002-2676-3781
  surname: Sato
  fullname: Sato, Takashi
– sequence: 12
  givenname: Masaharu
  orcidid: 0000-0002-4012-2518
  surname: Shinkai
  fullname: Shinkai, Masaharu
– sequence: 13
  givenname: Ryosuke
  orcidid: 0000-0003-0296-8843
  surname: Suzuki
  fullname: Suzuki, Ryosuke
– sequence: 14
  givenname: Yoshiharu
  orcidid: 0000-0001-9091-8285
  surname: Matsuura
  fullname: Matsuura, Yoshiharu
– sequence: 15
  givenname: Noritaka
  orcidid: 0000-0003-1363-2050
  surname: Hashii
  fullname: Hashii, Noritaka
– sequence: 16
  givenname: Yoshimasa
  orcidid: 0000-0001-6342-4087
  surname: Takahashi
  fullname: Takahashi, Yoshimasa
– sequence: 17
  givenname: Takeshi
  orcidid: 0000-0002-9972-6105
  surname: Inoue
  fullname: Inoue, Takeshi
– sequence: 18
  givenname: Kazuo
  orcidid: 0000-0002-0085-2057
  surname: Yamashita
  fullname: Yamashita, Kazuo
– sequence: 19
  givenname: Tomohiro
  orcidid: 0000-0002-6352-304X
  surname: Kurosaki
  fullname: Kurosaki, Tomohiro
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34623376$$D View this record in MEDLINE/PubMed
BookMark eNptkc9vFCEcxYlpY7fVm2czRw9S-TEwMxeTZqPVpIlJq14JMN_Z0szACkyT6j8v0-021vREgM97D973GB344AGhN5ScUtLWH25gOmWEUUoIf4FWVNQEd4K3B2hFCGO4nDdH6DilG0JoXQv5Eh3xWjLOG7lCf87HO6t9BX7jPEB0flOFocrXUF2dXV7hdfiJWRXBwjaHiI3z_YL0YdKuqEZnXU6VjSEl7GHOUY_u90Jon50JvYNUDSHuzCKMOkNf3bo4J0iv0OGgxwSvH9YT9OPzp-_rL_ji2_nX9dkFtrUgGcvBUEulGYTpesOa8tnWCuioNoQy3unONC2AAN6KoWdlx4FQDdLShjVc8hP0cee7nc0EvQW_PFNto5t0vFNBO_X0xrtrtQm3qpU1ZUIUg3cPBjH8miFlNblkYRy1hzAnxURLZMeJ5AV9-2_WY8i-8QKwHXDfWYRBlQZ1dmGJdqOiRC1jVWWsaj_WInr_n2jv-yz-F2cqpbc
CitedBy_id crossref_primary_10_1016_j_celrep_2022_110561
crossref_primary_10_1038_s41577_023_00897_3
crossref_primary_10_1371_journal_ppat_1012599
crossref_primary_10_1084_jem_20221786
crossref_primary_10_1126_science_abq0839
crossref_primary_10_1093_intimm_dxad017
crossref_primary_10_3390_v14071382
crossref_primary_10_1111_apm_13284
crossref_primary_10_1002_jmv_29893
crossref_primary_10_1038_s41467_024_54865_z
crossref_primary_10_3389_fimmu_2022_902260
crossref_primary_10_1002_jev2_12290
crossref_primary_10_1038_s41467_023_36295_5
crossref_primary_10_26508_lsa_202402774
crossref_primary_10_1016_j_celrep_2022_110318
crossref_primary_10_1016_j_bcp_2022_115335
crossref_primary_10_1021_acsinfecdis_3c00483
crossref_primary_10_1038_s44298_024_00067_9
crossref_primary_10_1084_jem_20241019
crossref_primary_10_1186_s12985_022_01818_x
Cites_doi 10.1038/s41586-020-2852-1
10.1038/s41586-020-2169-0
10.1038/s41467-021-21968-w
10.1073/pnas.1517719113
10.1093/bib/bbx108
10.1101/cshperspect.a013359
10.1016/j.immuni.2020.10.023
10.1093/intimm/dxz049
10.1038/s41586-020-2179-y
10.1016/j.cell.2015.06.026
10.1038/s41392-020-00402-5
10.1038/s41577-020-00480-0
10.1093/nar/gkn180
10.1038/s41586-020-2349-y
10.1038/s41564-020-0688-y
10.1038/nm.3985
10.1128/JVI.02608-13
10.1038/s41586-020-2456-9
10.1038/s41594-020-0480-y
10.1126/science.abc5902
10.1093/intimm/dxaa012
10.1038/s41467-021-21240-1
10.1101/2021.04.23.441195
10.1038/nature12711
10.3201/eid2607.200092
10.1038/s41467-021-23074-3
10.1126/science.abd2321
10.1038/s41596-020-0394-5
10.1038/s41467-020-19568-1
10.1038/s41598-021-85202-9
10.1038/s41594-021-00596-4
10.1016/j.cell.2020.06.043
10.1126/science.aac7263
10.1080/21655979.2020.1814683
10.1016/j.immuni.2018.07.005
10.3389/fmicb.2018.02991
10.1016/j.cell.2020.10.043
10.1128/JVI.02377-07
10.1126/science.1234150
10.1126/science.abc7424
10.1084/jem.20200866
10.1016/j.cell.2020.08.012
10.1038/s41577-020-00410-0
10.1093/bioinformatics/btv359
10.1016/j.cell.2021.03.036
10.1128/JVI.02499-09
10.1038/s41586-020-2381-y
10.1038/srep22666
10.1016/j.chom.2019.04.003
10.1016/j.cell.2020.06.025
10.1038/s41591-021-01294-w
10.1016/j.cell.2020.12.015
10.1038/srep05885
ContentType Journal Article
Copyright 2021 Shinnakasu et al.
2021 Shinnakasu et al. 2021
Copyright_xml – notice: 2021 Shinnakasu et al.
– notice: 2021 Shinnakasu et al. 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1084/jem.20211003
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Glycan-engineered RBD induces bnAbs for SARS-CoVs
EISSN 1540-9538
ExternalDocumentID PMC8641255
34623376
10_1084_jem_20211003
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Japan Agency for Medical Research and Development
  grantid: JP20fk0108104
– fundername: Japan Society for the Promotion of Science
  grantid: JP19H01028
– fundername: ;
  grantid: JP19H01028
– fundername: ;
  grantid: JP20fk0108104; JP21fk0108534
GroupedDBID ---
-~X
18M
29K
2WC
36B
4.4
53G
5GY
5RE
5VS
AAYXX
ABOCM
ABZEH
ACGFO
ACNCT
ACPRK
ADBBV
AENEX
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C45
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EMB
F5P
F9R
GX1
H13
HYE
IH2
KQ8
L7B
N9A
O5R
O5S
OK1
P2P
P6G
R.V
RHI
SJN
TR2
TRP
UHB
W8F
WOQ
CGR
CUY
CVF
ECM
EIF
FRP
NPM
RHF
RPM
7X8
5PM
ID FETCH-LOGICAL-c450t-6fb1c16bf5b9db272028c5e91ab01239a9b78ee5e385fd29b73e01ae6c1727363
ISSN 0022-1007
1540-9538
IngestDate Thu Aug 21 14:05:29 EDT 2025
Thu Jul 10 22:38:39 EDT 2025
Thu Jan 02 22:40:54 EST 2025
Thu Apr 24 23:02:20 EDT 2025
Tue Jul 01 00:41:16 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
License 2021 Shinnakasu et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c450t-6fb1c16bf5b9db272028c5e91ab01239a9b78ee5e385fd29b73e01ae6c1727363
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
R. Shinnakasu and S. Sakakibara contributed equally to this paper.
Disclosures: R. Shinnakasu, S. Sakakibara, and T. Kurosaki reported a patent to "glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses" pending. N. Sax and K. Yamashita reported personal fees from KOTAI Biotechnologies, Inc. outside the submitted work. No other disclosures were reported.
ORCID 0000-0003-3241-4737
0000-0002-3495-9936
0000-0001-6342-4087
0000-0002-4012-2518
0000-0003-3157-5870
0000-0001-6770-1918
0000-0002-0085-2057
0000-0003-1363-2050
0000-0001-9091-8285
0000-0002-9972-6105
0000-0002-2676-3781
0000-0003-0296-8843
0000-0002-7079-3339
0000-0002-8573-987X
0000-0002-6352-304X
0000-0002-5369-3424
0000-0002-2757-2792
0000-0003-2057-9198
0000-0002-3965-6715
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8641255
PMID 34623376
PQID 2580693063
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8641255
proquest_miscellaneous_2580693063
pubmed_primary_34623376
crossref_citationtrail_10_1084_jem_20211003
crossref_primary_10_1084_jem_20211003
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-06
PublicationDateYYYYMMDD 2021-12-06
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-06
  day: 06
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of experimental medicine
PublicationTitleAlternate J Exp Med
PublicationYear 2021
Publisher Rockefeller University Press
Publisher_xml – name: Rockefeller University Press
References 2023072802122067400_bib20
Garcia-Beltran (2023072802122067400_bib13) 2021; 184
Wang (2023072802122067400_bib47) 2020; 11
Liu (2023072802122067400_bib28) 2020; 5
Barnes (2023072802122067400_bib2) 2020; 588
Chen (2023072802122067400_bib7) 2021; 27
Valkenburg (2023072802122067400_bib43) 2016; 6
Hoffmann (2023072802122067400_bib16) 2021; 184
Bajic (2023072802122067400_bib1) 2019; 25
Wang (2023072802122067400_bib46) 2015; 162
Menachery (2023072802122067400_bib29) 2015; 21
Shi (2023072802122067400_bib38) 2020; 584
Bournazos (2023072802122067400_bib4) 2020; 20
Tajiri-Tsukada (2023072802122067400_bib42) 2020; 11
Impagliazzo (2023072802122067400_bib17) 2015; 349
Smatti (2023072802122067400_bib39) 2018; 9
Lau (2023072802122067400_bib24) 2020; 26
Dai (2023072802122067400_bib8) 2021; 21
Lam (2023072802122067400_bib23) 2020; 583
Katoh (2023072802122067400_bib21) 2019; 20
Wacharapluesadee (2023072802122067400_bib44) 2021; 12
Wec (2023072802122067400_bib49) 2020; 369
Korber (2023072802122067400_bib22) 2020; 182
Dodev (2023072802122067400_bib10) 2014; 4
Letko (2023072802122067400_bib26) 2020; 5
Tani (2023072802122067400_bib52) 2010; 84
Nie (2023072802122067400_bib31) 2020; 15
Song (2023072802122067400_bib40) 2021; 12
Brouwer (2023072802122067400_bib6) 2020; 369
Pinto (2023072802122067400_bib32) 2020; 583
Yuan (2023072802122067400_bib50) 2020; 369
Rockx (2023072802122067400_bib34) 2008; 82
Breitling (2023072802122067400_bib5) 2013; 5
Liu (2023072802122067400_bib27) 2020; 53
Sauer (2023072802122067400_bib36) 2021; 28
Robbiani (2023072802122067400_bib33) 2020; 584
Wang (2023072802122067400_bib48) 2021; 12
Eggink (2023072802122067400_bib12) 2014; 88
Leach (2023072802122067400_bib25) 2019; 31
Sato (2023072802122067400_bib35) 2020; 32
Walls (2023072802122067400_bib45) 2020; 183
Starr (2023072802122067400_bib41) 2020; 182
Gupta (2023072802122067400_bib15) 2015; 31
Dereeper (2023072802122067400_bib9) 2008; 36
Duan (2023072802122067400_bib11) 2018; 49
Menachery (2023072802122067400_bib30) 2016; 113
Ge (2023072802122067400_bib14) 2013; 503
Barnes (2023072802122067400_bib3) 2020; 182
Inoue (2023072802122067400_bib18) 2021; 218
Yoshida (2023072802122067400_bib53) 2021; 11
Jardine (2023072802122067400_bib19) 2013; 340
Shang (2023072802122067400_bib37) 2020; 581
Zhou (2023072802122067400_bib51) 2020; 27
References_xml – volume: 588
  start-page: 682
  year: 2020
  ident: 2023072802122067400_bib2
  article-title: SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
  publication-title: Nature.
  doi: 10.1038/s41586-020-2852-1
– volume: 583
  start-page: 282
  year: 2020
  ident: 2023072802122067400_bib23
  article-title: Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins
  publication-title: Nature.
  doi: 10.1038/s41586-020-2169-0
– volume: 12
  start-page: 1715
  year: 2021
  ident: 2023072802122067400_bib48
  article-title: A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-21968-w
– volume: 113
  start-page: 3048
  year: 2016
  ident: 2023072802122067400_bib30
  article-title: SARS-like WIV1-CoV poised for human emergence
  publication-title: Proc. Natl. Acad. Sci. USA.
  doi: 10.1073/pnas.1517719113
– volume: 20
  start-page: 1160
  year: 2019
  ident: 2023072802122067400_bib21
  article-title: MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization
  publication-title: Brief. Bioinform.
  doi: 10.1093/bib/bbx108
– volume: 5
  year: 2013
  ident: 2023072802122067400_bib5
  article-title: N-linked protein glycosylation in the endoplasmic reticulum
  publication-title: Cold Spring Harb. Perspect. Biol.
  doi: 10.1101/cshperspect.a013359
– volume: 53
  start-page: 1272
  year: 2020
  ident: 2023072802122067400_bib27
  article-title: Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2020.10.023
– volume: 31
  start-page: 771
  year: 2019
  ident: 2023072802122067400_bib25
  article-title: Requirement for memory B-cell activation in protection from heterologous influenza virus reinfection
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxz049
– volume: 581
  start-page: 221
  year: 2020
  ident: 2023072802122067400_bib37
  article-title: Structural basis of receptor recognition by SARS-CoV-2
  publication-title: Nature.
  doi: 10.1038/s41586-020-2179-y
– volume: 162
  start-page: 160
  year: 2015
  ident: 2023072802122067400_bib46
  article-title: Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy
  publication-title: Cell.
  doi: 10.1016/j.cell.2015.06.026
– volume: 5
  start-page: 282
  year: 2020
  ident: 2023072802122067400_bib28
  article-title: RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00402-5
– volume: 21
  start-page: 73
  year: 2021
  ident: 2023072802122067400_bib8
  article-title: Viral targets for vaccines against COVID-19
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00480-0
– volume: 36
  issue: Web Server issue
  year: 2008
  ident: 2023072802122067400_bib9
  article-title: Phylogeny.fr: robust phylogenetic analysis for the non-specialist
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkn180
– volume: 583
  start-page: 290
  year: 2020
  ident: 2023072802122067400_bib32
  article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
  publication-title: Nature.
  doi: 10.1038/s41586-020-2349-y
– volume: 5
  start-page: 562
  year: 2020
  ident: 2023072802122067400_bib26
  article-title: Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-0688-y
– volume: 21
  start-page: 1508
  year: 2015
  ident: 2023072802122067400_bib29
  article-title: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
  publication-title: Nat. Med.
  doi: 10.1038/nm.3985
– volume: 88
  start-page: 699
  year: 2014
  ident: 2023072802122067400_bib12
  article-title: Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain
  publication-title: J. Virol.
  doi: 10.1128/JVI.02608-13
– volume: 584
  start-page: 437
  year: 2020
  ident: 2023072802122067400_bib33
  article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals
  publication-title: Nature.
  doi: 10.1038/s41586-020-2456-9
– volume: 27
  start-page: 950
  year: 2020
  ident: 2023072802122067400_bib51
  article-title: Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/s41594-020-0480-y
– volume: 369
  start-page: 643
  year: 2020
  ident: 2023072802122067400_bib6
  article-title: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  publication-title: Science.
  doi: 10.1126/science.abc5902
– volume: 32
  start-page: 499
  year: 2020
  ident: 2023072802122067400_bib35
  article-title: Repurposing the psoriasis drug Oxarol to an ointment adjuvant for the influenza vaccine
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxaa012
– volume: 12
  start-page: 972
  year: 2021
  ident: 2023072802122067400_bib44
  article-title: Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-21240-1
– ident: 2023072802122067400_bib20
  doi: 10.1101/2021.04.23.441195
– volume: 503
  start-page: 535
  year: 2013
  ident: 2023072802122067400_bib14
  article-title: Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
  publication-title: Nature.
  doi: 10.1038/nature12711
– volume: 26
  start-page: 1542
  year: 2020
  ident: 2023072802122067400_bib24
  article-title: Possible Bat Origin of Severe Acute Respiratory Syndrome Coronavirus 2
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid2607.200092
– volume: 12
  start-page: 2938
  year: 2021
  ident: 2023072802122067400_bib40
  article-title: Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-23074-3
– volume: 369
  start-page: 1119
  year: 2020
  ident: 2023072802122067400_bib50
  article-title: Structural basis of a shared antibody response to SARS-CoV-2
  publication-title: Science.
  doi: 10.1126/science.abd2321
– volume: 15
  start-page: 3699
  year: 2020
  ident: 2023072802122067400_bib31
  article-title: Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay
  publication-title: Nat. Protoc.
  doi: 10.1038/s41596-020-0394-5
– volume: 11
  start-page: 5752
  year: 2020
  ident: 2023072802122067400_bib47
  article-title: Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19568-1
– volume: 11
  issue: 1
  year: 2021
  ident: 2023072802122067400_bib53
  article-title: SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals
  publication-title: Sci. Rep
  doi: 10.1038/s41598-021-85202-9
– volume: 28
  start-page: 478
  year: 2021
  ident: 2023072802122067400_bib36
  article-title: Structural basis for broad coronavirus neutralization
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/s41594-021-00596-4
– volume: 182
  start-page: 812
  year: 2020
  ident: 2023072802122067400_bib22
  article-title: Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.06.043
– volume: 349
  start-page: 1301
  year: 2015
  ident: 2023072802122067400_bib17
  article-title: A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen
  publication-title: Science.
  doi: 10.1126/science.aac7263
– volume: 11
  start-page: 984
  year: 2020
  ident: 2023072802122067400_bib42
  article-title: Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies
  publication-title: Bioengineered.
  doi: 10.1080/21655979.2020.1814683
– volume: 49
  start-page: 301
  year: 2018
  ident: 2023072802122067400_bib11
  article-title: Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2018.07.005
– volume: 9
  start-page: 2991
  year: 2018
  ident: 2023072802122067400_bib39
  article-title: Viral-Induced Enhanced Disease Illness
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2018.02991
– volume: 183
  start-page: 1367
  year: 2020
  ident: 2023072802122067400_bib45
  article-title: Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.10.043
– volume: 82
  start-page: 3220
  year: 2008
  ident: 2023072802122067400_bib34
  article-title: Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge
  publication-title: J. Virol.
  doi: 10.1128/JVI.02377-07
– volume: 340
  start-page: 711
  year: 2013
  ident: 2023072802122067400_bib19
  article-title: Rational HIV immunogen design to target specific germline B cell receptors
  publication-title: Science.
  doi: 10.1126/science.1234150
– volume: 369
  start-page: 731
  year: 2020
  ident: 2023072802122067400_bib49
  article-title: Broad neutralization of SARS-related viruses by human monoclonal antibodies
  publication-title: Science.
  doi: 10.1126/science.abc7424
– volume: 218
  year: 2021
  ident: 2023072802122067400_bib18
  article-title: Exit from germinal center to become quiescent memory B cells depends on metabolic reprograming and provision of a survival signal
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20200866
– volume: 182
  start-page: 1295
  year: 2020
  ident: 2023072802122067400_bib41
  article-title: Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.08.012
– volume: 20
  start-page: 633
  year: 2020
  ident: 2023072802122067400_bib4
  article-title: The role of IgG Fc receptors in antibody-dependent enhancement
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00410-0
– volume: 31
  start-page: 3356
  year: 2015
  ident: 2023072802122067400_bib15
  article-title: Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data
  publication-title: Bioinformatics.
  doi: 10.1093/bioinformatics/btv359
– volume: 184
  start-page: 2384
  year: 2021
  ident: 2023072802122067400_bib16
  article-title: SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
  publication-title: Cell.
  doi: 10.1016/j.cell.2021.03.036
– volume: 84
  start-page: 2798
  year: 2010
  ident: 2023072802122067400_bib52
  article-title: Involvement of Ceramide in the Propagation of Japanese Encephalitis Virus
  publication-title: J. Virol
  doi: 10.1128/JVI.02499-09
– volume: 584
  start-page: 120
  year: 2020
  ident: 2023072802122067400_bib38
  article-title: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
  publication-title: Nature.
  doi: 10.1038/s41586-020-2381-y
– volume: 6
  start-page: 22666
  year: 2016
  ident: 2023072802122067400_bib43
  article-title: Stalking influenza by vaccination with pre-fusion headless HA mini-stem
  publication-title: Sci. Rep.
  doi: 10.1038/srep22666
– volume: 25
  start-page: 827
  year: 2019
  ident: 2023072802122067400_bib1
  article-title: Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope
  publication-title: Cell Host Microbe.
  doi: 10.1016/j.chom.2019.04.003
– volume: 182
  start-page: 828
  year: 2020
  ident: 2023072802122067400_bib3
  article-title: Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.06.025
– volume: 27
  start-page: 717
  year: 2021
  ident: 2023072802122067400_bib7
  article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01294-w
– volume: 184
  start-page: 476
  year: 2021
  ident: 2023072802122067400_bib13
  article-title: COVID-19-neutralizing antibodies predict disease severity and survival
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.12.015
– volume: 4
  start-page: 5885
  year: 2014
  ident: 2023072802122067400_bib10
  article-title: A tool kit for rapid cloning and expression of recombinant antibodies
  publication-title: Sci. Rep.
  doi: 10.1038/srep05885
SSID ssj0014456
Score 2.4754448
Snippet Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding...
Shinnakasu et al. show that the glycan engineering immunogens of SARS-CoV-2 spike receptor-binding domain (RBD) elicited higher proportions of the...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
SubjectTerms Amino Acid Motifs
Animals
Antibodies, Viral - immunology
Broadly Neutralizing Antibodies - immunology
COVID-19 - genetics
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Female
Humans
Infectious Disease and Host Defense
Male
Mice
Mice, Inbred BALB C
Polysaccharides - genetics
Polysaccharides - immunology
Protein Domains
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Severe acute respiratory syndrome-related coronavirus - genetics
Severe acute respiratory syndrome-related coronavirus - immunology
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Title Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses
URI https://www.ncbi.nlm.nih.gov/pubmed/34623376
https://www.proquest.com/docview/2580693063
https://pubmed.ncbi.nlm.nih.gov/PMC8641255
Volume 218
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkKa9oHEvA2QkeJoCSRo7yeM0ARXSEKIb9C2yE0fN1iZVmyBtvPLDOcdxLm2ZBLxEie04Ur-vx-f4XEzI6zS2U1xGLAGrm-UxKSwh4C7kfpJKDtJQYO7w2Wc-vvA-Tdl0MPjVi1qqSvk2vvljXsn_oAptgCtmyf4Dsu2k0AD3gC9cAWG4_hXGH-fXKMRUV1OwcflPTr5OrNPim-Ueg0hTS7Cs0QbWGSxJsRBYKGSexeg10OuklatK73nc1EmLZSYLjC_UUYh6Mp30Atrpj2xVrU3g4WVHtZ5iu3FowLbvfjLL8lxciXWlwb0u2g5ovMrQ96E3ZGfVTGWtSBILAZTSu7rjbFUs2p7vZrv7S2GNK7MImz0M19HxIKYCtpG7no2e5KAvmN1OMldNtPWOxLcDDyW-wqoCaMzqigllD_zlQqM_8kDRG_lbZbfNQl533SF3XTA2dMr4tA0UAouTcZMyAR971__UAdlvXt7Ua3aMle2Y254Sc35I7hmQ6ElNpftkoPIHZP_MYPSQ_KwZRXuMokVKgVG0YxTdZhStGUUNo-guo2jHKAqMon1GUcOoR-Tiw_vz07FljuewYo_ZpcVT6cQOlymTYSLRn-8GMVOhIyQq6qEIpR8oxdQoYGniwtNI2Y5QPNZKMx89Jnt5kaunhMZK-AmoTYFkoadkKG0hGcwtEjRREjYkx82PG8Wmdj0eoTKPdAxF4EWAStSgMiRv2tHLumbLLeNeNThFIFTRUyZyVVTryGWBjWeEchjzpMatnakBfEj8DUTbAViwfbMnz2a6cHvAPbAn2LNb5zwiB93f4znZK1eVegFKbylfak7-BtSwsxU
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glycan+engineering+of+the+SARS-CoV-2+receptor-binding+domain+elicits+cross-neutralizing+antibodies+for+SARS-related+viruses&rft.jtitle=The+Journal+of+experimental+medicine&rft.au=Shinnakasu%2C+Ryo&rft.au=Sakakibara%2C+Shuhei&rft.au=Yamamoto%2C+Hiromi&rft.au=Wang%2C+Po-Hung&rft.date=2021-12-06&rft.eissn=1540-9538&rft.volume=218&rft.issue=12&rft_id=info:doi/10.1084%2Fjem.20211003&rft_id=info%3Apmid%2F34623376&rft.externalDocID=34623376
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1007&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1007&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1007&client=summon